Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

Slides:

Advertisements

Similar presentations

5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.

Advertisements

 GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose  Type 2 diabetics little incretin effect  Reduced GLP-1 secretion.

Diabetes in the 21 st Century 2010 Update. American Diabetes Association 2010 Guidelines – Diagnostic Criteria A1C > or = 6.5% is included as diagnostic.

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.

Diabetes Update Part 2 of 3 Division of Endocrinology

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

Part 2 of 2.  GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular.

The FATZO mouse as a Translational Model for the Development of Drugs for Obesity, Metabolic Syndrome and Diabetes. PreClinOmics, Inc. 1.

Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 4 of 5.

New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Supported by Virtual Poster Hall: Summary Slides Professor Stephan Matthaei Tuesday, September 15 th This Virtual Poster Hall session explores the relationship.

Small concise points on Insulin

Adult and Pediatric Dosages Based on Body Surface Area

2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2

Volume 384, Issue 9961, Pages (December 2014)

Copyright © 2015 by the American Osteopathic Association.

From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis Ann Intern Med.

Neal B, et al. Diabetes Care 2015;38:403–411

Cycloset®A Dopamine Receptor Agonist Cycloset® -Bromocriptine: Safety Trial: Post Hoc Analysis of Cumulative Percent MACE Endpoint Bromocriptine (Parlodel)

Canagliflozin: Real World Experience

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Updates on Emerging GLP-1 Receptor Agonists

Patient Case Discussions in T2D: What Intensification Plan Is Best?

Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence.

Nilotinib 300 mg bid Nilotinib 400 mg bid Imatinib 400 mg qd n Median

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Updates Abound.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Clinical Application of New CV Outcomes Data

GLP-1 Receptor Agonists: How Early Is Appropriate?

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type 2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

Novel Approaches to T1D Management

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.

Dual SGLT1/SGLT2 Inhibition in T1D

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.

Biopharmaceutics Pharmacy Technician.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Deep Dive: Examining Emerging GLP-1 RAs From a Clinical Perspective

Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Emerging Combination Injectable Therapy A New Era in Diabetes Care

ADA/EASD general recommendations for type 2 diabetes management (1).

Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.

Results of sensitivity analyses.

INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.

IGlarLixi SoloSTAR pen device and dose delivery of insulin glargine (units) and lixisenatide (µg) ranging from 15 units insulin glargine/5 µg lixisenatide.

The effect of VSG on body weight and body fat in GLP-1r KO mice.

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

Effect of empagliflozin on efficacy parameters at week 18.

Comorbid conditions and concomitant medications.

Glycemic control and body weight over 52 weeks.

ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,

Time course of HbA1c (A), FPG (B), body weight (C), SMPG (D), and lipase (E) from week 0 to week 26. Time course of HbA1c (A), FPG (B), body weight (C),

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Antihyperglycemic therapy in adults with type 2 diabetes

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Baseline characteristics of people who inject drugs enrolled in the Montreal Hepatitis C Cohort (2004–2017), by prescribed dosage of opioid agonist treatment,

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

Presentation transcript:

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists (13–18). Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists (13–18). Each square represents findings from one study. Drugs were tested as monotherapy or in combination with oral medications except as noted. *Finding reported as comparator in clinical study in another drug’s prescribing information. †Finding for drug in combination with insulin. QD, once daily. Deborah Hinnen Diabetes Spectr 2017;30:202-210 ©2017 by American Diabetes Association